☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
US
ARS Pharmaceuticals Reports the EC’s Approval of Eurneffy (Adrenaline Nasal Spray) to Treat Type I Allergic Reactions
August 26, 2024
Tris Pharma Initiates Pivotal P-III Study to Evaluate Cebranopadol for Moderate-to-Severe Acute Pain
August 22, 2024
Amgen’s Otezla (Apremilast) is now Accessible in The US to treat Moderate to Severe Pediatric Plaque Psoriasis
August 22, 2024
Regeneron Showcases Updated on BLA for Linvoseltamab to Treat R/R Multiple Myeloma (MM)
August 21, 2024
AstraZeneca’s Fasenra Receives NMPA’s Approval to Treat Severe Eosinophilic Asthma
August 21, 2024
Liquidia Corporation’s Yutrepia Receives the US FDA’s Tentative Approval to Treat PAH & PH-ILD
August 21, 2024
Load more...
Back to Home
Modal title
×
Modal body text goes here.